Tarsus Pharmaceuticals, Inc.

Verified identity

Start with the filing record

The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.

Ticker: TARS
CIK: 0001819790
Exchange: Nasdaq
Universe updated: 2026-08-22

Open SEC filings

Market price

Latest quoteOpens Google

TickerGrove coverage

Latest on Tarsus Pharmaceuticals, Inc.

Companies

Tarsus closes Alkeus acquisition, adding Phase 3 Stargardt drug

Tarsus now holds worldwide rights to investigational ALK-001, expanding its eye-care pipeline into late-stage retinal disease. NORTHSTAR Phase 3 topline data are anticipated in 2029.

Published 09-06-2026 · Event 09-04-2026 · Page updated 09-08-2026 · Tarsus Pharmaceuticals, Inc.

Research foundation

Read the filing with the right frame

Company analysis

Revenue, EPS and guidance answer different earnings questions

Revenue is the top-line amount recognized from a company’s activities under its accounting policy.

Earnings reading room →

Company analysis

The three financial statements describe one business from different angles

The income statement records revenue and expenses over a period.

Company research desk →

Investing basics

Stocks, ETFs and indexes are different objects

A stock is an ownership interest in one company.

Company research desk →